The present invention relates to the field of organic synthesis and more specifically it concerns a process for the dehydrogenation of compound of formula (I) catalyzed by palladium (Pd.sup.0) in elemental metallic form.

Synthesis and characterization of novel tamibarotene forms suitable for pharmaceutical compositions in drug delivery systems to treat human or warm-blooded mammal diseases.

The present invention relates to artemisinic acid glycoconjugate compounds. More particularly, the present invention relates to a glycoconjugate compound of formula (I) and a process for the preparation of artemisinic acid glycoconjugate compound of formula (I) by using 1,3-dipolar cycloaddition chemistry starting from artemisinic acid.

##STR00001##

A resist composition comprising a base polymer and a sulfonium salt of iodized benzoic acid offers a high sensitivity and minimal LWR independent of whether it is of positive or negative tone.

The present invention relates to trans isomers of formula (I) ##STR00001## in the form of any one of its stereoisomers or a mixture thereof, and wherein the bold and hatched lines indicate a relative or absolute configuration; and one dotted line represents a carbon-carbon single bond and the other a carbon-carbon double bond; and their uses as perfuming ingredients (e.g. to impart vetiver/rooty notes), e.g. in consumer products.

Some embodiments of the invention include inventive catalysts (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions comprising the inventive catalysts. Some embodiments include methods of using the inventive catalysts (e.g., in hydrofluorination of an organic compound). Further embodiments include methods for making the inventive catalysts. Additional embodiments of the invention are also discussed herein.

A sulfuric acid ester containing a plurality of carbonyl groups or a salt thereof, and a surfactant. The sulfuric acid ester is a compound represented by the following formula:

R.sup.1C(O)R.sup.2C(O)R.sup.3OSO.sub.3X

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein; X is H, a metal atom, NR.sup.4.sub.4, imidazolium optionally containing a substituent, pyridinium optionally containing a substituent, or phosphonium optionally containing a substituent, where R.sup.4s are each H or an organic group and are the same as or different from each other; and any two of R.sup.1, R.sup.2, and R.sup.3 optionally bind to each other to form a ring.

Hierarchically porous ZSM-5 zeolites, having macropores, mesopores, and micropores are formed using a solid-state crystallization process. An aluminosilicate nanogel prepared with precursors, solvent, and a structure-directing agent is provided. The solvent is evaporated from the aluminosilicate nanogel at room temperature. The dried aluminosilicate nanogel is then heated to promote crystallization. The crystallized zeolites are calcined to remove the structure-directing agent.

Shown is a compound represented by formula (1). For example, R.sup.1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp.sup.1 is a single bond or alkylene having 1 to 10 carbons; M.sup.1 is methyl; and R.sup.2, M.sup.2 and M.sup.3 are hydrogen. ##STR00001##

The invention provides 20-nor-salvinorin A, an analog of the kappa-opioid agonist salvinorin A. The 20-nor-salvinorin A is an active kappa-opioid modulator and can be used for treatment of medical conditions wherein modulation of the kappa-opioid receptor is medically indicated, such as pain, pruritis, depression, or inflammation, or conditions implicating perception and consciousness. 20-nor-salvinorin A can be less additive when used in treatment compared to a mu-opioid receptor agonist, and 20-nor-salvinorin A is more stable in vivo than is parent compound salvinorin A. The invention further provides synthetic intermediates and procedures for preparation of 20-nor-salvinorin A.